In this video we discuss longer term results of the phase III SABRINA study, which tested the safety and efficacy of subcutaneous rituximab in patients with follicular lymphoma.
Andrew Davies, PhD
Advertisement
Articles by Andrew Davies, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies
2
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
3
Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer
4
Precision Medicine and the “Slow Death” of Transplant in Lymphoma
5